Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Therapeutic Rationale for mTOR Inhibition in Advanced Renal Cell Carcinoma

Published:2011-08-01 Issue:3 Volume:6 Page:214-221
ISSN:1574-8847
Container-title:Current Clinical Pharmacology
language:en
Short-container-title:CCP

Author:

D. Husseinzadeh Holleh,A. Garcia Jorge

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TFE3/PI3K/Akt/mTOR Axis in Renal Cell Carcinoma Affects Tumor Microenvironment;The American Journal of Pathology;2024-07

2. Circulating Biomarkers in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus in the Pre-nephrectomy Setting;Clinical Oncology;2023-03

3. Heterogeneity of Hippo signalling activity in different histopathologic subtypes of renal cell carcinoma;Journal of Cellular and Molecular Medicine;2022-12-07

4. Circular RNAs play roles in regulatory networks of cell signaling pathways in human cancers;Life Sciences;2022-11

5. GLUD1 suppresses renal tumorigenesis and development via inhibiting PI3K/Akt/mTOR pathway;Frontiers in Oncology;2022-09-20

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP